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It is underappreciated that cardiovascular (CV) disease is
the number one cause of death in women. In fact, women
are more likely to die after a myocardial infarction than
men (1). Conventional risk factors such as tobacco use,
diabetes, high triglycerides, and low high-density lipo-
protein portend a greater risk in women than in men (2-4).
Women are also more likely to suffer from nontraditio-
nal CV risk factors, such as systemic autoimmune
disorders, and women have unique risk factors such as
preeclampsia, gestational diabetes, and pregnancy-induced
hypertension, which are unmasked during pregnancy.
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Particularly concerning is several ominous trends such as an
increasing prevalence of hypertension in African-American
women and an epidemic of obesity and diabetes in
women. Despite this, most women are unaware of their risk
for heart disease, and commonly used clinical risk stratiﬁ-
cation tools such as the Framingham score underestimate
their lifetime risk. The identiﬁcation of women with
signiﬁcant coronary artery disease (CAD) is also compli-
cated by the fact that they often present with atypical
symptoms, such as fatigue, sleep disturbances, shortness of
breath, indigestion, or anxiety. Furthermore, the patho-
physiology of CAD is somewhat different in women than in
men. Women have less obstructive CAD and are more likely
to have a plaque rupture due to endothelial erosion. In fact,
in women, angina is often due to microvascular dysfunction
rather than signiﬁcant epicardial coronary stenosis, and
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tomatic counterparts.
In addition to the various clinical and pathophysiological
obstacles to detecting CAD in women, there are also several
challenges related to the most commonly used diagnostic
tests. Traditional treadmill stress testing is well-known to
have a limited sensitivity and speciﬁcity for the detection of
CAD in women (5). A moderate improvement in the diag-
nostic performance of traditional exercise stress testing is seen
with the addition of single photon emission computed
tomography (SPECT) or echocardiography imaging (6).
Stress testing with SPECT may be limited by attenuation
artifact, poor spatial resolution, and the need for ionizing
radiation. Limited acoustic windows and poor endocardial
deﬁnition can compromise the diagnostic capability of stress
echocardiography. Despite these limitations, both imaging
modalities are powerful tools for risk stratiﬁcation regardless
of sex (7). During the last decade, there has been increasing
interest in the use of newer imaging modalities, such as
cardiovascular magnetic resonance (CMR), cardiac computed
tomography (CCT), and positron emission tomography
(PET), to improve the detection of CAD. Advantages of
CMR include the absence of ionizing radiation and attenu-
ation artifacts; in fact, one recent study suggests that stress
CMR is superior to SPECT for the detection of CAD in
women (8) and that it also facilitates risk stratiﬁcation of
patients regardless of sex (9). The relatively high spatial
resolution of CMR allows for the detection of diffuse sub-
endocardial ischemia due to microvascular dysfunction, which
is also associated with a poor prognosis (10). Cardiac CT
allows for the direct visualization of coronary anatomy and
has proven to be accurate for the diagnosis of signiﬁcant
CAD, as well as being cost effective in the evaluation of
symptomatic women (11). Data from the multicenter
CONFIRM Registry show that the burden and extent of
CAD, as detected by CCT, can be used additionally as
a powerful risk stratiﬁcation tool (12). As with SPECT, an
important limitation of CCT is its need for ionizing radia-
tion, although radiation doses have been recently, signiﬁcantly
lowered with newer scanner technology.
The PET imaging is now performed in an increasing
number of centers worldwide and has an excellent diagnostic
performance for the detection of CAD. Advantages of PET
when compared with SPECT include improved image
quality, reductions in attenuation artifact, and an improved
safety proﬁle with a relatively low radiation dose. High
spatial resolution and less attenuation artifact with PET may
also allow for improved detection of microvascular
dysfunction. In this issue of the Journal, Kay et al. (13)
report on the inﬂuence of sex on risk stratiﬁcation with
stress myocardial perfusion PET. In this well-designed,
multicenter registry that included >6,000 men and
women, the authors showed that stress rubidum-82 (Rb-82)
PET provides clinically meaningful risk stratiﬁcation of both
men and women with suspected CAD. Compared to men:
1) women had a higher prevalence of low risk PET ﬁndings;
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PET scans; and 3) had a signiﬁcantly lower CAD mortality.
It is difﬁcult to know if these ﬁndings are entirely due to sex
effects or due to the fact that men in this cohort were more
likely to have known CAD, prior myocardial infarction,
prior revascularization, and higher pretest probability.
Interestingly, in the subgroup of individuals that had more
than 10% ischemic myocardium, women had a higher
relative hazard than men. The authors also demonstrated the
value of quantifying the burden of myocardial ischemia.
Women had a 1.59-fold increased risk of death due to CAD
for every 5% increase in ischemic burden. In fact, the annual
CAD mortality rose from 0.23% to 3.73% in women, as the
percent of hypoperfused myocardium at stress increased
from 0% to 50%. The unadjusted 5-year CAD mortality
ranged from 0.9% to 12.9% for 0% to 15% hypoperfused
myocardium at stress. The importance of ischemic burden
was unrelated to sex and persisted, even after accounting for
left ventricular ejection fraction.
The investigators also utilized the recently developed net
re-classiﬁcation improvement (NRI) (14) to demonstrate the
additive value of stress Rb-82 PET imaging to standard
clinical assessment for prediction of CV death in women.
The NRI attempts to determine how much more often
appropriate rather than inappropriate re-classiﬁcation of risk
occurs when a new tool is added to an existing risk strati-
ﬁcation model. Appropriate application of the NRI requires
the selection of previously deﬁned and clinically useful
categories of risk. In this study, the authors selected 3
reasonable categories of annualized CV risk (<1% for low
risk, 1% to 3% for intermediate risk, and >3% for high risk).
They found that stress Rb-82 PET imaging improved
the risk stratiﬁcation of approximately 12% of women (and
17% of men) with events and no net loss for those with
nonevents when compared with standard clinical assess-
ment. Although the NRI results are impressive, caution
is warranted in that the results could change if different
categories of risk are selected. One of the advantages of
PET is the ability to noninvasively quantify coronary ﬂow
reserve (15). It remains to be seen whether the inclusion of
such quantiﬁcation would further improve the NRI. An
important limitation of NRI is that it does not provide
insight into the magnitude of risk re-classiﬁcation (i.e., if the
risk re-classiﬁcation large, such as 5% to 20%, or if it was
much smaller, such as 5% to 5.3%).
Demonstrating improvement over existing clinical risk-
stratiﬁcation assessment models depends on the variables
included in the existing model. In this study, the authors
compared PET imaging to a clinical model that included age,
cardiac risk factors, symptoms, and a history of CAD.
However, each of the variables was simply categorized as
either present or not. As such, important clinical features
such as the severity of a speciﬁc risk factor or the classical
presentation of a symptom were not accounted for in the
model comparison. Additionally, all risk factors received
equal weighting in the model without accounting for anyvariability in the speciﬁc risk level (i.e., whether diabetes is
a worse risk factor than smoking). Although such clinical
reﬁnements may be valuable in understanding the true
additive value of a new diagnostic test, their inclusion may be
quite challenging. Another challenge for accurate determi-
nation of the ability of a diagnostic test to predict an adverse
event is to account for the effect of therapies that may have
been initiated in response to the result of the test itself.
For example, patients with a signiﬁcant burden of ischemia
may have undergone coronary revascularization that could
alter the probability of a subsequent CV event. Historically,
patients who were revascularized within a few months of
the index test have been censored from analysis in an
attempt to minimize test conﬁrmation bias. However, in
this study, the investigators opted not to censor any
patients, making the reasonable argument that several recent
large-scale, prospective, multicenter trials suggested that
patient outcomes were similar regardless of whether or not
revascularization was performed. How similar the present
patient population was to those in these studies is unclear.
In addition, whether this assumption holds true in individ-
uals with a moderate-to-large burden of ischemia is
unknown, and this is the focus of another large ongoing
National Institutes of Health-sponsored clinical trial (i.e., the
ISCHEMIA trial). Furthermore, given that this is a registry
study and not a randomized clinical trial, it is difﬁcult to
account for the variation in treatment strategies that may
have been applied and how this variation may have impacted
patient outcomes.
Because the assessment of CAD is complicated by
a variety of technical and clinical differences, including sex,
a distinct body of evidence for new diagnostic tests should be
collected for both men and women. The work by Kay et al.
(13) is a valuable addition to the evidence basis for stress
Rb-82 PET, and they conﬁrm the utility of stress Rb-82
PET as a CV risk stratiﬁcation tool in women with sus-
pected CAD. Additional prospective studies would further
enhance the stature of stress Rb-82 PET as an imaging tool
for risk stratifying women.
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